FDA Suspends Valneva's Chikungunya Vaccine License Following Severe Adverse Events in Elderly Patients
Key Insights
The US Food and Drug Administration has suspended the license for Valneva (search)'s Ixchiq chikungunya (search) vaccine following four additional cases of severe side effects, primarily affecting patients aged 70 to 82.
The suspension comes amid growing global chikungunya (search) threats, with Europe recording 27 outbreaks this year and the WHO warning of potential epidemic risks similar to the 2004 Indian Ocean outbreak.
Valneva (search)'s shares dropped over 26% following the announcement, though the company maintains its commitment to global vaccine access and continues investigating the reported adverse events.
The US Food and Drug Administration has suspended the license for Valneva (search)'s Ixchiq chikungunya (search) vaccine following reports of severe adverse effects, marking a significant setback for one of only two FDA-approved vaccines against the mosquito-borne disease. The French pharmaceutical company announced Monday that the FDA issued the suspension on Friday after four additional cases of serious side effects emerged, three involving patients aged 70 to 82.
"The suspension of the licence is effective immediately," Valneva (search) stated, confirming the regulatory action that affects the vaccine approved in 2023. The decision follows updated data from the Vaccine Adverse Event Reporting System, including cases reported outside the United States.
Safety Concerns in Elderly Populations
Of the four new adverse event cases, three involved individuals aged 70 to 82, including one 82-year-old patient who required hospitalization for two days before discharge. The remaining case involved a 55-year-old patient. Valneva (search) noted that all cases presented symptoms consistent with those previously documented in clinical trials and post-marketing surveillance, particularly among elderly individuals.
The regulatory scrutiny extends beyond US borders, with the European Medicines Agency (search) conducting its own review of adverse events earlier this year, particularly focusing on older patients. These reviews were prompted by mounting reports of adverse events following the vaccine's initial approval.
Market Impact and Financial Implications
The suspension announcement triggered a sharp market reaction, with Valneva (search)'s shares plummeting more than 26% on the Paris stock exchange. Despite the regulatory setback, the company indicated it is evaluating the financial impact but has not modified its revenue guidance. Ixchiq generated 7.5 million euros ($8.8 million) in sales during the first half of 2025.
Global Chikungunya Threat Escalates
The suspension comes at a critical time as chikungunya (search) continues to spread globally. The World Health Organization highlighted the risk of a major chikungunya epidemic in July, citing early warning signs similar to the 2004 outbreak in the Indian Ocean region that eventually affected nearly half a million people.
Europe has already recorded 27 chikungunya (search) outbreaks this year, establishing a new continental record according to the European Centre for Disease Prevention and Control (search). The virus, transmitted by Aedes mosquitoes, causes fever, severe joint and muscle pain, headache, nausea, fatigue, and rash. While rarely fatal, chikungunya can pose particular dangers to infants and elderly populations.
Public health experts have warned that climate change is expanding mosquito habitats, potentially making chikungunya (search) a future pandemic threat. Recent outbreaks have been confirmed in Kenya's Mombasa County, where the Kenya Medical Research Institute reported that 25 of 45 suspected cases tested positive.
Company Response and Future Plans
Valneva (search) CEO Thomas Lingelbach emphasized the company's continued commitment to vaccine access despite the regulatory challenges. "As we determine potential next steps, and as the clear threat of chikungunya (search) continues to escalate globally, Valneva remains fully committed to maintaining access to our vaccine as a global health tool for addressing and preventing outbreaks of this devastating illness," he stated.
The company aims to continue providing Ixchiq to countries where the product remains licensed and is working with partners to accelerate vaccine access in low- and middle-income chikungunya (search)-endemic countries. Valneva (search) stated it will continue investigating the reported cases in detail and take further steps in consultation with health authorities while reaffirming its commitment to safety standards and global vaccine access.